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Edited by Masayuki MiyasakaAbstract Human CC chemokine-4 (HCC-4)/CCL16 is a che-
moattractant for monocytes and lymphocytes. Although HCC-4
binds to multiple CC chemokine receptors, the receptor-mediated
signal transduction pathway induced by HCC-4 has not been
characterized. Human osteogenic sarcoma cells stably expressing
CCR1 were used to investigate HCC-4-mediated chemotaxis sig-
naling events via CCR1. The chemotactic activity of HCC-4 as
well as those of other CCR1-dependent chemokines including
MIP-1a/CCL3, RANTES/CCL5, and Lkn-1/CCL15 was inhib-
ited by the treatment of pertussis toxin, an inhibitor of Gi/Go pro-
tein, U73122, an inhibitor of phospholipase C (PLC), and
rottlerin, a speciﬁc inhibitor of protein kinase Cd (PKCd). These
results indicate that HCC-4-induced chemotaxis signaling is
mediated through Gi/Go protein, PLC, and PKCd. SB202190,
an inhibitor of p38 mitogen activated protein kinase, only blocked
the chemotactic activity of HCC-4, but not those of other CCR1-
dependent chemokines. SB202190 inhibited HCC-4-induced che-
motaxis in a dose-dependent manner (P < 0.01). HCC-4 induces
p38 activation in both a time and dose-dependent manner.
However, such p38 activation was not induced by other CCR1-
dependent chemokines. To further investigate the diﬀerential
eﬀect of HCC-4, the Ca2+ mobilization was examined. HCC-4
induced no intracellular Ca2+ ﬂux in contrast to other CCR1-
dependent chemokines. These results indicate that HCC-4 trans-
duces signals diﬀerently from other CCR1-dependent chemokines
and may play diﬀerent roles in the immune response.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Chemokines are small chemoattractant cytokines that in-
duce leukocyte accumulation at inﬂammatory sites and regu-
late leukocyte traﬃcking through lymphoid tissues [1]. There
are approximately 40 chemokines identiﬁed to date. Chemo-
kines are grouped into the four diﬀerent families CXC (a),
CC (b), C (c), and CX3C (d) by the spacing of two cysteines
in the N-terminal region of the molecule. CXC (a) chemokines
play an essential role in neutrophils [1]. CC (b) chemokines are*Corresponding author. Fax: +82 2 927 9028.
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doi:10.1016/j.febslet.2005.09.064eﬀective on migration of monocytes, T lymphocytes, basophils,
eosinophils, NK cells, and dendritic cells [2]. The only known
C (c) chemokine, lymphotactin, acts on T lymphocytes and
NK cells [3]. The CX3C (d) chemokine fractalkine is known
as a chemoattractant for T lymphocytes and monocytes [4].
Human CC chemokine-4 (HCC-4), also called LEC, NCC-4,
LMC and CCL16, was identiﬁed by searching the database of
expressed sequence tags [5–7]. HCC-4 has been known to bind
to multiple chemokine receptors, including CCR1, CCR2,
CCR5 and CCR8 [8,9]. HCC-4 chemoattracts both monocytes
and lymphocytes, but not neutrophils [5,6]. Recent studies
have demonstrated that HCC-4 increases tumor rejection, anti-
gen presentation of macrophages, T cell cytotoxicity, and
angiogenic activity of vascular endothelial cells [10–13].
Chemokine receptors belong to seven-transmembrane G-
protein coupled receptors (GPCRs). Based on the chemokine
class they bind, the receptors have been named CXCR1
through CXCR6, which bind CXC chemokines, CCR1
through CCR10, which bind CC chemokines, CX3CR1, which
binds CX3C chemokine, and XCR1, which binds C chemokine
[14]. CCR1 is expressed in a variety of immune cells, including
monocytes, lymphocytes, neutrophils, and eosinophils depend-
ing on the state of diﬀerentiation and activation of the cell [15].
It has been previously reported that CCR1 is associated with
the inﬂammatory immune response, including multiple sclero-
sis, transplantation rejection and atopy [16–18]. Signal trans-
duction pathways via CCR1 have been studied for several
chemokines [19–21]. Myeloid progenitor inhibitor factor-1
(MPIF-1) activates both G protein and PLC, resulting in
Ca2+ inﬂux, and regulates cytoskeletal remodeling through
PLA2 [19]. Lkn-1 induces chemotaxis signaling through Gi/
Go protein, phospholipase C (PLC) and protein kinase Cd
(PKCd) [20], and activates extracellular signal-related kinase
(ERK) [21].
Although there have been numerous reports regarding the
eﬀects of HCC-4, the signal transduction pathway induced
by HCC-4 is not well understood. In this study, we investi-
gated the mechanism of the HCC-4-induced chemotaxis signal
via CCR1 using human osteogenic sarcoma cells stably
expressing CCR1 (HOS/CCR1).2. Materials and methods
2.1. Materials
Dulbeccos modiﬁed Eagles medium (DMEM) and fetal bovine
serum (FBS) were purchased from Life Technologies, Inc. (Gaithers-
burg, MD). Recombinant human HCC-4, Lkn-1/CCL15, MIP-1a/blished by Elsevier B.V. All rights reserved.
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apolis, MN). Pertussis toxin (PTX), PD98059, U73122, rottlerin, Ro-
31-8425, and SB202190 were obtained from Calbiochem (San Diego,
CA). Fluo3-acetoxymethyl (ﬂuo3-AM) ester and pluronic F-127 were
purchased fromMolecular Probes (Eugene, OR). Rat tail collagen type
I was obtained from Sigma (St. Louis, MO). Anti-phospho-p38 anti-
body was purchased from Cell Signaling Technology (Beverly, MA).
2.2. Cell culture
Stable HOS cells expressing CCR1 [20,21] were grown in DMEM
supplemented with 10% heat-inactivated fetal bovine serum, penicillin
(100 U/ml), streptomycin (100 lg/ml), and puromycin (0.5 lg/ml).
2.3. Chemotaxis assay
Cell migration assay was performed using a 48-well microchamber
(Neuroprobe, Cabin John, MD) as previously described [22]. The
lower wells were ﬁlled with 28 ll buﬀer alone or with buﬀer containing
chemokine and a polyvinylpyrrolidone-free ﬁlter (Neuroprobe) with
10 lm pores was placed over lower well. Membranes were precoated
with RPMI 1640 containing rat tail collagen type I at 4 C overnight.
The upper wells were ﬁlled with 50 ll of HOS/CCR1 cells at 5 · 105
cells/ml in RPMI 1640 containing 1% BSA and 30 mM HEPES. The
chamber was incubated for 3 h at 37 C. After the polycarbonate ﬁlter
was removed, cells adhering to its upper surface were wiped oﬀ with a
ﬁlter wiper. A ﬁlter was dried, ﬁxed, and stained with Diﬀ-Quick (Bax-
ter, McGaw Park, IL). The cells of four randomly selected ﬁelds per
well were counted using Axiovert 25 (Carl Zeiss, Jena, Germany)
and Visus Image Analysis System (Foresthill Products, Foresthill,
CA). The chemotactic index (CI) is calculated from the number of cells
that migrated to the control.
2.4. Western blotting analysis
Cell extracts were prepared by homogenization in lysis buﬀer
(10 mM HEPES, 10 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1%
NP-40, 0.5 mM PMSF, 0.1 mM DTT, 0.1 mM Na3VO4, and protease
inhibitors). Protein samples (50 lg/well) were separated by a 10%
SDS–PAGE and transferred to nitrocellulose membranes. The blots
were incubated with anti-phospho-p38 antibody and developed with
the enhanced chemiluminescence detection system (Amersham Phar-
macia Biotech, Piscataway, NJ). The same membranes were stripped
and reprobed with anti-p38 antibody as an internal control.Fig. 1. HCC-4 induces cell migration in HOS cells expressing CCR1. HOS/C
MIP-1a (B), RANTES (C) or Lkn-1 (D) in microchamber and were allowed
cells that migrated was counted microscopically in two randomly selected ﬁeld
of cells migrating to the test chemokines divided by that migrating to the co
Data are expressed as mean CIs ± S.E.M. of three independent experiments2.5. Measurement of Ca2+ inﬂux
Kinetics of intracellular Ca2+ concentration was monitored as previ-
ously described [23]. Brieﬂy, cells were harvested, washed, and resus-
pended in HBSS containing 1 lM ﬂuo3-AM ester and 0.01%
pluronic F-127. After incubation for 30 min at 37 C, dye-loaded cells
were washed three times with Ca2+ assay buﬀer (135 mM NaCl,
3.6 mM KCl, 2.5 mM CaCl2 Æ 2H2O, 10 mM glucose, and 5 mM
HEPES, 0.1% BSA, pH 7.4), and incubated for 30 min at 37 C to al-
low complete de-esteriﬁcation of ﬂuo 3-AM ester. Chemokines were
added in a dose-dependent manner, and subsequently intracellular
Ca2+ concentration was analyzed at 488 nm of excitation wavelength
and 530 nm of emission wavelength on a FACSort cytoﬂuorimeter.
Baseline ﬂuorescence was monitored for 40 s before addition of chemo-
kines.
2.6. Statistical analysis
Data are expressed as means ± S.E.M. Statistical diﬀerences between
two groups were analyzed by using Students t test. The SPSS statisti-
cal software package (Version 10.0, Chicago, IL) was used for statisti-
cal analysis. The signiﬁcant value is deﬁned as P < 0.01.3. Results
3.1. HCC-4 induces chemotaxis in HOS cells expressing CCR1
Stable HOS cells expressing CCR1 (HOS/CCR1) were estab-
lished to investigate chemotaxis signaling through CCR1 [22].
It has been reported that CCR1 is expressed on the surface of
HOS/CCR1 cells [20]. A chemotaxis assay was performed to
investigate the chemotactic activity of HCC-4. As shown in
Fig. 1A, the maximum chemotactic activity of HCC-4 was de-
tected at a concentration of 1000 ng/ml. MIP-1a, RANTES
and Lkn-1 induced peak responses at 1, 100 and 100 ng/ml,
respectively (Fig. 1B–D). The chemotactic index of HCC-4
was comparable to those of other CCR1-dependent chemo-
kines. These results indicate that HCC-4 has a binding aﬃn-
ity for CCR1 much lower than those of other CCR1-
dependent chemokines but is as eﬃcient as MIP-1a, RANTESCR1 cells were applied to the indicated concentrations of HCC-4 (A),
to migrate for 3 h. Filters were stained with Diﬀ-Quick. The number of
s per well. The chemotactic index (CI) was calculated from the number
ntrols. Six replicate measurements are included in a single experiment.
.
Fig. 3. p38 MAPK is involved in HCC-4-induced chemotaxis signal-
ing. (A) HOS/CCR1 cells were pre-incubated in the absence (control)
or presence of 20 lM SB202190 (SB20) or 20 lM PD98059 (PD20).
Chemotactic responses to HCC-4 (1000 ng/ml, black bar), MIP-1a
(1 ng/ml, white bar), RANTES (100 ng/ml, thin hatched bar), or Lkn-1
(100 ng/ml, thick hatched bar) were measured as described in Section 2.
(B) HOS/CCR1 cells were pre-incubated in the absence (control) or
presence of the indicated concentrations of SB202190 (SB10, 10 lM;
SB20, 20 lM; SB40, 40 lM). Chemotactic activity in response to HCC-
4 (1000 ng/ml, black bar) was measured as described in Section 2. Six
replicate measurements are included in a single experiment. Data are
expressed as mean CIs ± S.E.M. of three independent experiments.
\\P < 0.01 is assessed as critical diﬀerence between control group and
inhibitor-treated group.
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concentrations.
3.2. HCC-4 transduces the chemotaxis signal through Gi/Go
protein, PLC and PKCd
Since we previously reported that Lkn-1 and MIP-1a medi-
ate chemotaxis signaling through Gi/Go protein, PLC, and
PKCd [20], we tested whether HCC-4 mediates cell migration
through the same signaling pathway. Both PTX and U73122
inhibited cell migration induced by CCR1-dependent chemo-
kines by up to 90–95% (P < 0.01) (Fig. 2). Rottlerin had an
inhibitory eﬀect on cell migration induced by CCR1-dependent
chemokines whereas Ro-31-8425, a blocker of classic PKC, did
not inhibit the chemotactic activities of CCR1-dependent che-
mokines. These results indicate that the chemotaxis event in re-
sponse to HCC-4 as well as other CCR1-dependent
chemokines involves Gi/Go protein, PLC and PKCd.
3.3. p38 MAPK is involved in HCC-4-induced chemotaxis
signaling
Mitogen activated protein kinase (MAPK), including p38
and ERK, plays important roles in integrin activation and cell
motility due to chemokines [24,25]. We investigated whether
MAPK is involved in HCC-4-induced chemotaxis signaling.
Cell migration induced by HCC-4 was inhibited by the p38
inhibitor SB202190 (Fig. 3A). However, chemotaxis triggered
by other CCR1-dependent chemokines was not aﬀected by
SB202190. To conﬁrm that p38 MAPK is involved in HCC-
4-mediated cell migration, we performed a chemotaxis assay
after dose-dependent treatment with SB202190. The number
of migrated cells induced by HCC-4 signiﬁcantly decreased
in a dose-dependent manner (P < 0.01) (Fig. 3B). The MEK
inhibitor PD98059 had no eﬀect on the chemoattraction of
CCR1-dependent chemokines. These results indicate that sig-
naling through p38 MAPK is involved in cell migration in-
duced by HCC-4 but not by other CCR1-dependent
chemokines.
3.4. HCC-4 induces p38 MAPK activation
Since p38 MAPK is required for HCC-4-induced chemotaxis
signaling, we examined whether HCC-4 induces p38 activa-Fig. 2. HCC-4 transduces the chemotaxis signal through Gi/Go
protein, PLC and PKCd. HOS/CCR1 cells were pre-incubated in the
absence (control) or presence of 100 ng/ml PTX, 1 lMU73122, 20 lM
rottlerin, or 50 nM Ro-31-8425. Chemotactic responses to HCC-4
(1000 ng/ml, black bar), MIP-1a (1 ng/ml, white bar), RANTES
(100 ng/ml, thin hatched bar), or Lkn-1 (100 ng/ml, thick hatched
bar) were measured as described in Section 2. Six replicate measure-
ments are included in a single experiment. Data are expressed as mean
CIs ± S.E.M. of three independent experiments. \\P < 0.01 is assessed
as signiﬁcant diﬀerence between control group and inhibitor-treated
group.tion. HOS/CCR1 cells were treated with 1000 ng/ml of HCC-
4 for diﬀerent time periods before being lysed and subsequently
analyzed for phosphorylation of p38 by Western blotting. As
shown in Fig. 4A, HCC-4 stimulated p38 activation with a
peak at 1 h. The dose dependence of p38 activation in response
to HCC-4 was determined and maximum p38 activation was
detected at 100–3000 ng/ml of HCC-4 (Fig. 4B). However,
the activation of p38 was not induced by other CCR1-depen-
dent chemokines. HCC-4 did not induce the ERK activation
(data not shown). These results indicate that HCC-4 diﬀeren-
tially stimulates p38 MAPK activation in comparison with
other CCR1-dependent chemokines.
3.5. HCC-4 has no eﬀect on Ca2+ mobilization
To further characterize the diﬀerential signaling induced by
HCC-4, another functional assay, a Ca2+ inﬂux, was per-
formed. Most chemokines increase the intracellular Ca2+
concentration after binding to their receptors. HOS/CCR1
cells were treated with diﬀerent concentrations of chemo-
kines, and alteration of the intracellular Ca2+ concentration
was measured. The transient intracellular Ca2+ ﬂux was in-
duced by chemokines MIP-1a, RANTES, and Lkn-1
(Fig. 5). However, the intracellular Ca2+ concentration was
not aﬀected by exposure of cells to HCC-4 (Fig. 5). This
result may indicate that HCC-4 plays a diﬀerent role in
the immune responses.
Fig. 5. HCC-4 does not induce Ca2+ mobilization. HOS/CCR1 cells
were incubated with 1 lM ﬂuo3-AM. Dye-loaded cells were stimulated
with the indicated concentrations (20 ng/ml, dotted line; 100 ng/ml,
thin line; 500 ng/ml, thick line) of HCC-4, MIP-1a, RANTES, or Lkn-
1 and subsequently monitored for 120 s. Data are expressed as
representative of two independent experiments.
Fig. 4. HCC-4 induces p38 activation. HOS/CCR1 cells were serum
starved with 0.5% serum for 24 h and stimulated with HCC-4 (1000 ng/
ml), MIP-1a (1 ng/ml), RANTES (100 ng/ml), or Lkn-1 (100 ng/ml) for
the indicated time up to 12 h (A). For dose dependence experiments,
serum starved HOS/CCR1 cells were stimulated with the indicated
concentrations of HCC-4 for 1 h (B). Proteins were extracted, separated
on 10% SDS–polyacrylamide gels (50 lg/lane) and transferred to
nitrocellulose membrane. The level of activation was detected by
Western blotting with anti-phospho-p38 antibody. The membrane was
stripped and reprobed with anti-p38 antibody as an internal control.
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Although HCC-4 plays a role in tumor rejection and antigen
presentation, the HCC-4-induced cellular mechanism has not
been elucidated [10,12]. In the present study, we examined
HCC-4-induced chemotaxis signaling via CCR1 in HOS/
CCR1 cells. Our results demonstrate that (1) HCC-4 tranduces
the chemotaxis signal via PTX-sensitive Gi/Go protein, PLC,
and PKCd. (2) Cell migration induced by HCC-4 involves
the p38 signaling unlike other CCR1-dependent chemokines
MIP-1a, RANTES, and Lkn-1. (3) HCC-4 activates p38 in
both a time and dose-dependent manner. (4) HCC-4 has no ef-
fect on intracellular Ca2+ mobilization.
There is a controversy regarding the CC chemokine recep-
tors to which HCC-4 binds. It has been known that HCC-4
interacts with CCR1 and CCR8 [8]. However, it has been re-
ported that HCC-4 is a functional ligand for CCR1, CCR2,
and CCR5 [9]. Therefore, we investigated the HCC-4-induced
signal transduction pathway via CCR1. Since human phago-
cytes and lymphocytes express a variety of CC chemokine
receptors, stable HOS cell line overexpressing CCR1 was used
in this study as a model system. The sensitivity to chemokines
and the chemotactic activity of HOS/CCR1 cells were compa-
rable to human peripheral immune cells [22].
The mechanisms that regulate cell migration involve multi-
ple signaling pathways depending on the chemokines, chemo-
kine receptors and cell types. The PI3 kinase, MAPK, and
PKC signaling pathways have been shown to be involved in
cell migration induced by chemokines [25–27]. During chemo-
kine receptor activation, GDP that is bound to the a subunit of
G-protein receptors is released, leading to the rapid binding of
GTP and the subsequent dissociation of b/c subunits. The re-
lease of these b/c subunits initiates a cascade of multiple intra-
cellular events. Classically, PLC and PKC are activated [20].
Besides activation of the G protein, JAK/STAT activation ex-
ists in the downstream pathway following chemokine binding
[28]. We performed a chemotaxis assay to examine signaling
molecules associated with HCC-4-induced chemotaxis using
various inhibitors. Our data show that HCC-4-induced chemo-
taxis signaling involves PTX-sensitive Gi/Go protein, PLC, and
PKCd like other CCR1-dependent chemokines.
To further understand HCC-4-induced chemotaxis signal-
ing, the involvement of MAPK in HCC-4-induced chemotaxis
was examined using a cell migration assay. HCC-4-induced
chemoattraction was blocked in the presence of SB202190,
but not in the presence of PD98059. Both inhibitors had no
eﬀect on chemotaxis in response to other CCR1-dependent
chemokines. These results suggest that among the CCR1-
dependent chemokines, only HCC-4 also induces the chemo-
taxis signals through p38 MAPK. Diﬀerential eﬀects of
CCR1-dependent chemokines via CCR1 in neutrophils have
been reported [29]. HCC-4 is quite divergent from other
CCR1-dependent chemokines in the amino acid sequence [5].
HCC-4 has a less than 30% sequence homology to other
CCR1-dependent chemokines, and contains an unusual C-ter-
minal extension and a diﬀerent N-terminal sequence that is
needed for receptor activation [5]. This structural diﬀerence
may be one of the possible causes for the diﬀerential signaling
induced by HCC-4. After interacting with CCR1, HCC-4 un-
like other CCR1-dependent chemokines may transduce the sig-
nal through the divergent signaling pathways. Besides the G
protein/PLC/PKCd pathway, the p38 MAPK pathway may
6048 I.S. Kim et al. / FEBS Letters 579 (2005) 6044–6048be activated by tyrosine kinase or serine/threonine kinase. A
detailed signal transduction mechanism is currently under
investigation. p38 MAPK has been reported to play an impor-
tant role in chemotactic response of human monocytic THP-1
cells [24,25]. We investigated whether HCC-4 mediates the che-
motaxis signal through p38 MAPK in THP-1 cells. THP-1 cell
migration in response to HCC-4 was induced via G protein,
PLC, PKC, and p38 MAPK, similar to results for HOS/
CCR1 cells (data not shown).
Chemokines induce intracellular events, resulting in receptor
desensitization and cytoskeleton organization for cell migra-
tion [19,21]. Since p38 MAPK is associated with HCC-4-in-
duced chemotaxis signaling, and we previously reported that
Lkn-1 activates ERK [20], we examined whether p38 MAPK
and ERK are both activated by HCC-4. After the treatment
with HCC-4, p38 activation was observed. However, other
CCR1-dependent chemokines did not activate p38 MAPK.
These results indicate that the intracellular event of MAPK
activation that is induced by HCC-4 is unique in comparison
with other CCR1-dependent chemokines.
Chemokines are known to cause Ca2+ inﬂux after binding to
their receptors. Our results show that MIP-1a, RANTES and
Lkn-1 all increase the intracellular Ca2+ concentration. How-
ever, HCC-4 has no eﬀect on Ca2+ mobilization. It has been
previously reported that HCC-4 is not able to induce Ca2+
mobilization in lymphocytes and monocytes [5]. In contrast,
recent studies have demonstrated that HCC-4 induces tran-
sient Ca2+ inﬂux in CCR1-transfected cells at high concentra-
tions (1000 ng/ml) in comparison with other CCR1-dependent
chemokines [8,9]. Although we performed Ca2+ inﬂux assays at
HCC-4 concentrations of 1000 and 3000 ng/ml, the intracellu-
lar Ca2+ concentration in HOS/CCR1 cells was not aﬀected by
HCC-4 (data not shown).
In the present study, we have characterized the HCC-4-in-
duced chemotaxis signaling pathway. Cell migration induced
by HCC-4 involves Gi/Go protein, PLC, and PKCd. p38
MAPK is also uniquely involved in HCC-4-induced chemo-
taxis. HCC-4 has no eﬀect on Ca2+ mobilization, unlike other
CCR1-dependent chemokines. It has been known that chemo-
kines that bind to the same chemokine receptor transduce a
signal through the same signaling pathway. However, our data
from a chemotaxis assay using CCR1-transfected HOS and
various CCR1-dependent chemokines showed that there exist
the diﬀerential signal transduction pathways according to the
type of chemokines in spite of their interacting with the same
chemokine receptor CCR1. Our results may provide a clue
to elucidate the molecular mechanism of cell movement and
intracellular events induced by HCC-4, and to understand
the diﬀerential regulatory mechanisms of immune responses.
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